Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      WebMD Announces Third Quarter Financial Results

      WebMD Updates Financial Guidance for 2011


      News provided by

      WebMD

      Nov 02, 2011, 04:00 ET

      Share this article

      Share this article


      NEW YORK, Nov. 2, 2011 /PRNewswire/ -- WebMD Health Corp. (Nasdaq: WBMD), the leading source of health information, today announced financial results for its third quarter ended September 30, 2011.

      For the quarter ended September 30, 2011:

      • Revenue was $135.1 million, compared to $135.3 million in the prior year period.

      • Earnings before interest, taxes, non-cash and other items ("Adjusted EBITDA") was $43.5 million, compared to $44.6 million in the prior year period, a decrease of 2%.

      • Net income was $14.2 million or $0.24 per diluted share compared to $13.6 million or $0.22 per diluted share in the prior year period. Net income would have been $11.9 million or $0.20 per diluted share in the current period as compared to $16.0 million or $0.26 per diluted share in the prior year period, without the effect, in the current period, of an after-tax loss on investments of $(0.7) million and after-tax income from discontinued operations of $3.0 million and, in the prior year period, of an after-tax loss on convertible notes of $(1.4) million and an after-tax loss from discontinued operations of $(1.0) million.  

      As indicated in early October, third quarter revenue was at the low end of the financial guidance range provided by WebMD in August and Adjusted EBITDA for the quarter exceeded that prior guidance.

      “We are working closely with each of our major customers to put forward a portfolio of digital solutions as they finalize their 2012 marketing budgets,” said Wayne Gattinella, President and CEO, WebMD. “While I am not satisfied with our recent results, I firmly believe that our company has the market leadership and the demonstrated experience to leverage our assets in a large and still underdeveloped marketplace for the long-term.”

      Revenue Highlights

      Public portal advertising and sponsorship revenue increased 2% to $115.0 million, compared to $113.1 million in the prior year period. Traffic to the WebMD Health Network continued to grow, reaching an average of 107.3 million unique users per month and total traffic of 2.24 billion page views during the third quarter, increases of 29% and 26%, respectively, from a year ago. Traffic growth was primarily driven by increased traffic to WebMD owned and operated sites, which averaged 87.8 million unique users per month, and page views of 2.06 billion, increases of 31% and 27%, respectively, from a year ago.  Beginning January 1, 2012, the WebMD Health Network will not include any non-owned affiliate sites.

      Private portal services revenue decreased 10% to $20.1 million, compared to $22.2 million in the prior year period. The base of large employers and health plans using WebMD’s private Health and Benefits portals during the third quarter was 121.

      Balance Sheet Highlights

      During the quarter, WebMD repurchased approximately 2.05 million shares of its common stock for a total of $67 million.

      As of September 30, 2011, WebMD had $1.1 billion in cash and cash equivalents and $800 million in aggregate principal amount of convertible notes outstanding.

      After the end of the third quarter, WebMD repurchased approximately 775,000 shares of its common stock for a total of $22.5 million. On October 13, 2011, WebMD increased its authorized buyback program by $75 million. Currently, WebMD has approximately $90 million available under its buyback program.

      Financial Guidance  

      WebMD updated its financial guidance for the fourth quarter and full year 2011, as follows:

      For the fourth quarter of 2011, WebMD expects:

      • Revenue to be approximately $147 million to $157 million, compared to $168.5 million in the prior year period. Advertising revenue is expected to represent 86% of revenue and private portal revenue is expected to represent 14% of revenue.
      • Adjusted EBITDA to be approximately $53 million to $61 million, compared to $69.1 million in the prior year period.
      • Income from continuing operations to be approximately $15 million to $20 million, compared to $33.8 million in the prior year period.  

      For the year ended December 31, 2011, WebMD expects:  

      • Revenue to be approximately $555 million to $565 million, compared to $534.5 million in the prior year. Advertising revenue is expected to represent 86% of revenue and private portal revenue is expected to represent 14% of revenue.
      • Adjusted EBITDA to be approximately $180 million to $187 million, compared to $173.6 million in the prior year.
      • Income from continuing operations to be approximately $60 million to $65 million, compared to $52.3 million in the prior year.  

      The changes to the Company’s financial guidance for the remainder of 2011 are the result of several factors. Principally:

      • The revenue contribution of third quarter sales to fourth quarter revenue is expected to be less than anticipated and significantly less than historical experience. The delivery of the services sold in the third quarter is weighted more toward 2012 than previously anticipated.  

      • The revenue contribution of fourth quarter sales to fourth quarter revenue is expected to be less than anticipated and historical experience. WebMD has historically benefited from greater media buying in the fourth quarter when biopharmaceutical and consumer products customers commit unspent promotional dollars as their budget year closes.

      The Company believes that the lower than expected fourth quarter revenue resulting from sales activity in both the third and fourth quarters is primarily a result of a more cautious business outlook by many of its large customers for the second half of 2011.

      “I see substantial growth opportunities for WebMD,” said Martin J. Wygod, Chairman, WebMD. “With the pharmaceutical industry spend on digital marketing stuck at 5%, we understand our mission and will intensify our effort to roll out new products as well as demonstrate to our customers the unique WebMD capabilities that we believe will provide superior return on their marketing investment. We will take the steps necessary to ensure the Company’s long term growth and to maximize shareholder value.”

      WebMD is providing a schedule (attached to this press release) to reflect updated financial guidance.

      Analyst and Investor Conference Call

      WebMD will hold a conference call with investors and analysts to discuss its third quarter results and revised financial guidance at 4:45 p.m. (Eastern) today. The call can be accessed at www.wbmd.com (in the Investor Relations section). A replay of the audio webcast will be available at the same web address.

      About WebMD

      WebMD Health Corp. (Nasdaq: WBMD) is the leading provider of health information services, serving consumers, physicians, healthcare professionals, employers, and health plans through our public and private online portals, mobile platforms and health-focused publications.

      The WebMD Health Network includes WebMD Health, Medscape, MedicineNet, emedicineHealth, RxList, theheart.org, drugs.com and Medscape Education.

      All statements contained in this press release and the related analyst and investor conference call, other than statements of historical fact, are forward-looking statements, including those regarding:   guidance on our future financial results and other projections or measures of our future performance; market opportunities and our ability to capitalize on them; and the benefits expected from new or updated products or services and from other potential sources of additional revenue. These statements speak only as of the date of this press release, are based on our current plans and expectations, and involve risks and uncertainties that could cause actual future events or results to be different than those described in or implied by such forward-looking statements.  These risks and uncertainties include those relating to:  market acceptance of our products and services; our relationships with customers and strategic partners; and changes in economic, political or regulatory conditions or other trends affecting the healthcare, Internet and information technology industries.  Further information about these matters can be found in our Securities and Exchange Commission filings. Except as required by applicable law or regulation, we do not undertake any obligation to update our forward-looking statements to reflect future events or circumstances.

      This press release, and the accompanying tables, include both financial measures in accordance with accounting principles generally accepted in the United States of America, or GAAP, as well as certain non-GAAP financial measures.  The tables attached to this press release include reconciliations of these non-GAAP financial measures to GAAP financial measures. In addition, an “Explanation of Non-GAAP Financial Measures” is attached to this press release as Annex A.  

      WebMD®, Medscape®, eMedicine®, MedicineNet®, RxList®, Subimo®, Medsite®, Summex® and Medscape® Mobile are trademarks of WebMD Health Corp. or its subsidiaries.

      WEBMD HEALTH CORP.

      CONSOLIDATED STATEMENTS OF OPERATIONS

      (In thousands, except per share data, unaudited)














      Three Months Ended


      Nine Months Ended





      September 30,


      September 30,





      2011


      2010


      2011


      2010












      Revenue 


      $ 135,138


      $ 135,305


      $ 408,116


      $ 366,042

      Cost of operations 


      49,097


      47,610


      148,698


      135,972

      Sales and marketing 


      29,597


      28,957


      94,161


      86,789

      General and administrative 


      22,787


      22,964


      67,614


      62,350

      Depreciation and amortization 


      6,781


      6,935


      19,929


      20,268

      Interest income 


      21


      21


      88


      3,850

      Interest expense 


      5,862


      1,797


      14,836


      10,106

      Loss on convertible notes 


      -


      2,232


      -


      16,970

      Gain (loss) on investments


      (1,150)


      (131)


      14,679


      (22,977)

      Other income (expense), net


      -


      107


      (53)


      (92)

      Income from continuing operations before income










      tax provision (benefit)


      19,885


      24,807


      77,592


      14,368


      Income tax provision (benefit)


      8,645


      10,193


      32,606


      (4,140)

      Income from continuing operations


      11,240


      14,614


      44,986


      18,508


      Income (loss) from discontinued operations, net of tax


      2,994


      (1,024)


      10,388


      (1,024)

      Net income


      $   14,234


      $   13,590


      $   55,374


      $   17,484












      Basic income (loss) per common share:










      Income from continuing operations


      $       0.19


      $       0.25


      $       0.77


      $       0.33


      Income (loss) from discontinued operations


      0.06


      (0.02)


      0.18


      (0.01)

      Net income


      $       0.25


      $       0.23


      $       0.95


      $       0.32












      Diluted income (loss) per common share:










      Income from continuing operations


      $       0.19


      $       0.24


      $       0.75


      $       0.31


      Income (loss) from discontinued operations


      0.05


      (0.02)


      0.17


      (0.02)

      Net income


      $       0.24


      $       0.22


      $       0.92


      $       0.29












      Weighted-average shares outstanding used in










      computing  income (loss) per common share:









           Basic


      57,461


      58,095


      57,913


      54,602

           Diluted


      58,698


      61,435


      59,882


      58,660



      WEBMD HEALTH CORP.

      CONSOLIDATED SUPPLEMENTAL FINANCIAL INFORMATION

      (In thousands, unaudited)






















      Three Months Ended


      Nine Months Ended




      September 30,


      September 30,




      2011


      2010


      2011


      2010

      Revenue










      Public portal advertising and sponsorship


      $ 115,033


      $ 113,078


      $ 346,504


      $ 299,927


      Private portal services


      20,105


      22,227


      61,612


      66,115




      $ 135,138


      $ 135,305


      $ 408,116


      $ 366,042











      Earnings before interest, taxes, non-cash










      and other items ("Adjusted EBITDA") (a)


      $   43,465


      $   44,578


      $ 126,612


      $ 104,536











      Interest, taxes, non-cash and other items  (b)










      Interest income


      21


      21


      88


      3,850


      Interest expense


      (5,862)


      (1,797)


      (14,836)


      (10,106)


      Income tax (provision) benefit


      (8,645)


      (10,193)


      (32,606)


      4,140


      Depreciation and amortization


      (6,781)


      (6,935)


      (19,929)


      (20,268)


      Non-cash stock-based compensation


      (9,808)


      (8,804)


      (28,969)


      (23,605)


      Loss on convertible notes


      -


      (2,232)


      -


      (16,970)


      Gain (loss) on investments


      (1,150)


      (131)


      14,679


      (22,977)


      Other income (expense), net


      -


      107


      (53)


      (92)

      Income from continuing operations


      11,240


      14,614


      44,986


      18,508


      Income (loss) from discontinued operations, net of tax


      2,994


      (1,024)


      10,388


      (1,024)

      Net income


      $   14,234


      $   13,590


      $   55,374


      $   17,484











      (a)

      See Annex A-Explanation of Non-GAAP Financial Measures.









      (b)

      Reconciliation of Adjusted EBITDA to net income (loss).











      WEBMD HEALTH CORP.

      CONDENSED CONSOLIDATED BALANCE SHEETS

      (In thousands, unaudited)
















      September 30, 2011


      December 31, 2010

      Assets





      Cash and cash equivalents


      $  1,101,286


      $    400,501

      Accounts receivable, net


      117,938


      134,448

      Prepaid expenses and other current assets


      13,172


      12,161

      Deferred tax assets


      21,204


      23,467

             Total current assets


      1,253,600


      570,577







      Property and equipment,  net


      58,064


      61,516

      Goodwill


      202,104


      202,104

      Intangible assets, net


      20,656


      22,626

      Deferred tax assets


      62,613


      71,125

      Other assets


      32,318


      14,254

      Total Assets


      $  1,629,355


      $    942,202







      Liabilities and Stockholders' Equity





      Accrued expenses


      $       51,141


      $      53,181

      Deferred revenue


      90,673


      97,043

      Liabilities of discontinued operations


      1,810


      17,327

           Total current liabilities


      143,624


      167,551







      2.25% convertible notes due 2016


      400,000


      -

      2.50% convertible notes due 2018


      400,000


      -

      Other long-term liabilities


      22,403


      21,756







      Stockholders' equity


      663,328


      752,895







      Total Liabilities and Stockholders' Equity


      $  1,629,355


      $    942,202



      WEBMD HEALTH CORP.

      CONSOLIDATED STATEMENTS OF CASH FLOWS

      (In thousands, unaudited)























      Nine Months Ended







      September 30,







      2011


      2010

      Cash flows from operating activities:






      Net income


      $      55,374


      $   17,484


      Adjustments to reconcile consolidated net income to net cash provided by






       operating activities:







      (Income) loss from discontinued operations, net of tax


      (10,388)


      1,024



      Depreciation and amortization


      19,929


      20,268



      Non-cash interest, net


      2,702


      4,862



      Non-cash stock-based compensation


      28,969


      23,605



      Deferred income taxes


      5,378


      (17,260)



      Loss on convertible notes


      -


      16,970



      (Gain) loss on investments


      (14,679)


      22,977



      Changes in operating assets and liabilities:








      Accounts receivable


      16,510


      (2,206)




      Prepaid expenses and other, net


      1,238


      (3,006)




      Accrued expenses and other long-term liabilities


      (176)


      1,695




      Deferred revenue


      (6,370)


      3,413





      Net cash provided by continuing operations


      98,487


      89,826





      Net cash used in discontinued operations


      (136)


      (17,082)





      Net cash provided by operating activities


      98,351


      72,744










      Cash flows from investing activities:






      Proceeds from sales of available-for-sale securities


      -


      361,852


      Proceeds received from ARS option


      16,561


      407


      Purchases of property and equipment


      (16,061)


      (20,329)


      Finalization of sale price of discontinued operations


      -


      (1,430)





      Net cash provided by investing activities


      500


      340,500










      Cash flows from financing activities:






      Proceeds from exercise of stock options


      26,435


      57,168


      Cash used for withholding taxes due on stock-based awards


      (6,730)


      (76,559)


      Net proceeds from issuance of the 2.50% Notes and 2.25% Notes


      774,745


      -


      Repurchases of 1.75% Notes and 3 1/8% Notes


      -


      (94,475)


      Purchases of treasury stock


      (217,427)


      (420,948)


      Excess tax benefit on stock-based awards


      24,911


      14,003





      Net cash provided by (used in) financing activities


      601,934


      (520,811)

      Net increase in cash and cash equivalents


      700,785


      (107,567)

      Cash and cash equivalents at beginning of period


      400,501


      459,766

      Cash and cash equivalents at end of period


      $ 1,101,286


      $ 352,199



      WEBMD HEALTH CORP.

      NET INCOME PER COMMON SHARE

      (In thousands, except per share data, unaudited)



























      Three Months Ended


      Nine Months Ended





      September 30,


      September 30,





      2011


      2010


      2011


      2010













      Numerator:










      Income from continuing operations


      $11,240


      $14,614


      $44,986


      $18,508



      Effect of participating non-vested restricted stock


      (70)


      (152)


      (320)


      (222)


      Income from continuing operations- Basic and Diluted


      $11,170


      $14,462


      $44,666


      $18,286













      Income (loss) from discontinued operations, net of tax


      $  2,994


      $ (1,024)


      $10,388


      $ (1,024)



      Effect of participating non-vested restricted stock


      (19)


      12


      (74)


      12


      Income (loss) from discontinued operations, net of tax - Basic and Diluted


      $  2,975


      $ (1,012)


      $10,314


      $ (1,012)
























      Denominator:










      Weighted-average shares — Basic


      57,461


      58,095


      57,913


      54,602



      Employee stock options and restricted stock


      1,237


      3,340


      1,969


      4,058


      Adjusted weighted-average shares after assumed conversions — Diluted


      58,698


      61,435


      59,882


      58,660
























      Basic income (loss) per common share:











      Income from continuing operations


      $    0.19


      $    0.25


      $    0.77


      $    0.33



      Income (loss) from discontinued operations


      0.06


      (0.02)


      0.18


      (0.01)


      Net income


      $    0.25


      $    0.23


      $    0.95


      $    0.32













      Diluted income (loss) per common share:











      Income from continuing operations


      $    0.19


      $    0.24


      $    0.75


      $    0.31



      Income (loss) from discontinued operations


      0.05


      (0.02)


      0.17


      (0.02)


      Net income


      $    0.24


      $    0.22


      $    0.92


      $    0.29



      WebMD Health Corp.

      Updated Financial Guidance for the Quarter and Year Ended December 31, 2011

      (in millions, except per share amounts)















      Nine Months Ended



      Quarter Ended


      Year Ended



      September 30, 2011



      December 31, 2011


      December 31, 2011



      Actual



      Guidance Range


      Guidance Range













      Revenue


      $        408.1



      $ 147.0


      $ 157.0


      $ 555.1


      $ 565.1













      Earnings before interest, taxes, depreciation, amortization












       and other non-cash items ("Adjusted EBITDA") (a)


      $        126.6



      $   53.4


      $   60.9


      $ 180.0


      $ 187.5













      Interest, taxes, depreciation, amortization and other non-cash items (b)












      Interest expense, net


      (14.7)



      (5.9)


      (5.9)


      (20.6)


      (20.6)

      Depreciation and amortization


      (19.9)



      (8.1)


      (7.1)


      (28.0)


      (27.0)

      Non-cash stock-based compensation


      (29.0)



      (12.0)


      (11.0)


      (41.0)


      (40.0)

      Gain (loss) on investments


      14.7



      (1.2)


      (1.2)


      13.5


      13.5

      Other expense


      (0.1)



      -


      -


      (0.1)


      (0.1)

      Pre-tax income from continuing operations


      77.6



      26.2


      35.7


      103.8


      113.3













      Income tax provision


      (32.6)



      (11.4)


      (15.4)


      (44.0)


      (48.0)













      Income from continuing operations


      45.0



      14.8


      20.3


      59.8


      65.3













      Income from discontinued operations, net of tax


      10.4



      -


      -


      10.4


      10.4













      Net income


      $         55.4



      $   14.8


      $   20.3


      $   70.2


      $   75.7













      Income from continuing operations per share:












        Basic


      $         0.77



      $   0.26


      $   0.36


      $   1.02


      $   1.12

        Diluted


      $         0.75



      $   0.25


      $   0.34


      $   0.99


      $   1.08













      Net income per share:












        Basic


      $         0.95



      $   0.26


      $   0.36


      $   1.20


      $   1.29

        Diluted


      $         0.92



      $   0.25


      $   0.34


      $   1.16


      $   1.25

























      Weighted-average shares outstanding used in computing per share amounts:












       Basic


      57.9



      56.0


      56.0


      58.0


      58.0

       Diluted


      59.9



      57.5


      69.0


      60.0


      60.0

























      (a) See Annex A - Explanation of Non-GAAP Financial Measures













      (b) Reconciliation of Adjusted EBITDA to income from continuing operations

























      Additional information regarding income per share calculations:

          -     Both basic and diluted income per share reflect a reduction to income of $0.2 million and $0.6 million for the fourth quarter and full year, respectively, to consider the effect of restricted stock.

          -     Convertible Notes are not expected to be dilutive for the full year

          -     Convertible Notes are expected to impact diluted income per share during the fourth quarter as follows:

                          -  Low end of guidance range: Convertible Notes are not expected to be dilutive.

                          -  High end of guidance range: Reflects an increase to income of $1.7 million and $1.6 million for the interest expense (net of tax) on the 2.50% and 2.25%  Notes, respectively, and the diluted share count reflects an additional 6.1 million and 5.4 million shares, related to the 2.50% and 2.25% Notes, respectively.



      Additional information regarding fourth quarter and full year forecast:

          -     2011 guidance includes actual gains on investments during the nine months ended September 30, 2011 and forecasted amortization of the ARS Option for the three months ending December 31, 2011, but excludes any potential gains on investments during the three months ending December 31, 2011.




      ANNEX A

      Explanation of Non-GAAP Financial Measures

      The accompanying WebMD Health Corp. press release and the attached financial information and guidance include both financial measures in accordance with U.S. generally accepted accounting principles, or GAAP, as well as non-GAAP financial measures.  The non-GAAP financial measures represent earnings before interest, taxes, non-cash and other items (which we refer to as "Adjusted EBITDA") and related per share amounts.  Adjusted EBITDA should be viewed as supplemental to, and not as an alternative for, "income from continuing operations" or "net income" calculated in accordance with GAAP.  The financial information and guidance accompanying the press release include reconciliations of non-GAAP financial measures to GAAP financial measures.  

      Adjusted EBITDA is used by our management as an additional measure of our company's performance for purposes of business decision-making, including developing budgets, managing expenditures, and evaluating potential acquisitions or divestitures.  Period-to-period comparisons of Adjusted EBITDA help our management identify additional trends in our company's financial results that may not be shown solely by period-to-period comparisons of income from continuing operations or net income.  In addition, we use Adjusted EBITDA in the incentive compensation programs applicable to some of our employees in order to evaluate our company's performance.  Our management recognizes that Adjusted EBITDA has inherent limitations because of the excluded items, particularly those items that are recurring in nature.  In order to compensate for those limitations, management also reviews the specific items that are excluded from Adjusted EBITDA, but included in income from continuing operations or net income, as well as trends in those items.  The amounts of those items are set forth, for the applicable periods, in the reconciliations of Adjusted EBITDA to income from continuing operations or to net income that accompany our press releases and disclosure documents containing non-GAAP financial measures, including the reconciliations contained in the accompanying press release attachments.

      We believe that the presentation of Adjusted EBITDA is useful to investors in their analysis of our results for reasons similar to the reasons why our management finds it useful and because it helps facilitate investor understanding of decisions made by management in light of the performance metrics used in making those decisions.  In addition, as more fully described below, we believe that providing Adjusted EBITDA, together with a reconciliation of Adjusted EBITDA to income from continuing operations or to net income, helps investors make comparisons between our company and other companies that may have different capital structures, different effective income tax rates and tax attributes, different capitalized asset values and/or different forms of employee compensation.  However, Adjusted EBITDA is intended to provide a supplemental way of comparing our company with other public companies and is not intended as a substitute for comparisons based on income from continuing operations or net income.  In making any comparisons to other companies, investors need to be aware that companies use different non-GAAP measures to evaluate their financial performance.  Investors should pay close attention to the specific definition being used and to the reconciliation between such measures and the corresponding GAAP measures provided by each company under applicable SEC rules.

      The following is an explanation of the items excluded by us from Adjusted EBITDA but included in income from continuing operations and net income:

      • Depreciation and Amortization.  Depreciation and amortization expense is a non-cash expense relating to capital expenditures and intangible assets arising from acquisitions that are expensed on a straight-line basis over the estimated useful life of the related assets.  We exclude depreciation and amortization expense from Adjusted EBITDA because we believe that (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of our business operations and (ii) such expenses can vary significantly between periods as a result of new acquisitions and full amortization of previously acquired tangible and intangible assets.  Accordingly, we believe that this exclusion assists management and investors in making period-to-period comparisons of operating performance.  Investors should note that the use of tangible and intangible assets contributed to revenue in the periods presented and will contribute to future revenue generation and should also note that such expense will recur in future periods.

      • Stock-Based Compensation Expense.  Stock-based compensation expense is a non-cash expense arising from the grant of stock-based awards to employees.  We believe that excluding the effect of stock-based compensation from Adjusted EBITDA assists management and investors in making period-to-period comparisons in its operating performance because (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of our business operations and (ii) such expenses can vary significantly between periods as a result of the timing of grants of new stock-based awards, including grants in connection with acquisitions.  Additionally, we believe that excluding stock-based compensation from Adjusted EBITDA assists management and investors in making meaningful comparisons between our operating performance and the operating performance of other companies that may use different forms of employee compensation or different valuation methodologies for their stock-based compensation.  Investors should note that stock-based compensation is a key incentive offered to employees whose efforts contributed to the operating results in the periods presented and are expected to contribute to operating results in future periods.  Investors should also note that such expenses will recur in the future.  Stock-based compensation expenses included in the Consolidated Statement of Operations are summarized as follows:







      Three Months Ended


      Nine Months Ended






      September 30,


      September 30,






      2011

      2010


      2011

      2010








      Non-cash stock-based compensation included in:







      Cost of operations


      $    1,718

      $   1,889


      $    5,677

      $    5,153


      Sales and marketing


      $    2,286

      $   1,867


      $    6,865

      $    5,749


      General and administrative


      $    5,804

      $   5,048


      $  16,427

      $  12,703




      • Interest Income and Expense.  Interest income is associated with the level of marketable debt securities and other interest bearing accounts in which we invest, as well as with interest expense arising from our company's capital structure (including non-cash interest expense relating to our convertible notes).  Interest income and expense varies over time due to a variety of financing transactions and due to acquisitions and divestitures that we have entered into or may enter into in the future.  We have, in the past, issued convertible debentures, repurchased shares in cash tender offers and repurchased shares and convertible debentures through other repurchase transactions, and completed the divestiture of certain businesses.  We exclude interest income and interest expense from Adjusted EBITDA (i) because these items are not directly attributable to the performance of our business operations and, accordingly, their exclusion assists management and investors in making period-to-period comparisons of operating performance and (ii) to assist management and investors in making comparisons to companies with different capital structures.  Investors should note that interest income and expense will recur in future periods.  The following provides detail regarding the components of interest expense of our convertible notes:







      Three Months Ended


      Nine Months Ended






      September 30,


      September 30,






      2011

      2010


      2011

      2010








      Non-cash interest expense







      1.75% Convertible Notes


      $          --

      $      --


      $            --

      $      885


      3 1/8% Convertible Notes


      $          --

      $   977


      $            --

      $   4,264


      2.50% Convertible Notes


      $       456

      $      --


      $      1,305

      $         --


      2.25% Convertible Notes


      $       647

      $      --


      $      1,397

      $         --


      Cash interest expense








      1.75% Convertible Notes


      $          --

      $      --


      $            --

      $   1,564


      3 1/8% Convertible Notes


      $          --

      $   820


      $            --

      $   3,392


      2.50% Convertible Notes


      $    2,500

      $      --


      $     7,194

      $         --


      2.25% Convertible Notes


      $    2,250

      $      --


      $     4,925

      $         --




      • Income Tax Provision (Benefit).  We maintain a valuation allowance on a portion of our net deferred tax assets (including our net operating loss carryforwards), the amount of which may change from quarter to quarter based on factors that are not directly related to our results for the quarter.  The valuation allowance is either reversed through the statement of operations or additional paid-in capital.  The timing of such reversals has not been consistent and as a result, our income tax expense can fluctuate significantly from period to period in a manner not directly related to our operating performance.  We exclude the income tax provision (benefit) from Adjusted EBITDA (i) because we believe that the income tax provision (benefit) is not directly attributable to the underlying performance of our business operations and, accordingly, its exclusion assists management and investors in making period-to-period comparisons of operating performance and (ii) to assist management and investors in making comparisons to companies with different tax attributes.  Investors should note that income tax provision (benefit) will recur in future periods.

      • Other Items.  We engage in other activities and transactions that can impact our income from continuing operations and net income.  In recent periods, these other items have included, but were not limited to, (i) legal expenses relating to the Department of Justice investigation, (ii) gain or loss on repurchases and conversions of our convertible notes, (iii) a reduction of certain sales and use tax contingencies resulting from the expiration of certain applicable statutes of limitations, and (iv) gain or loss on investments.  We exclude these other items from Adjusted EBITDA because we believe these activities or transactions are not directly attributable to the performance of our business operations and, accordingly, their exclusion assists management and investors in making period-to-period comparisons of operating performance.  Investors should note that some of these other items may recur in future periods.

      SOURCE WebMD

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.